Olivier Loeillot is recorded as Board Member and CEO at Repligen Corp (RGEN). The newest filing on record that lists Olivier Loeillot as Board Member and CEO at Repligen Corp (RGEN) is dated April 2, 2026. Repligen Corp reported in an 8-K filed June 14, 2024 that Olivier Loeillot was appointed member of the Board, effective September 1, 2024. Repligen Corp reported in an 8-K filed June 14, 2024 that Olivier Loeillot was appointed President and Chief Executive Officer, effective September 1, 2024. Repligen Corp reported in an 8-K filed October 2, 2023 that Olivier Loeillot was appointed President and Chief Commercial Officer, effective October 2, 2023. The proxy statement of Repligen Corp reports total compensation of $6,114,771 for Olivier Loeillot in fiscal 2025, including a base salary of $860,000. Disclosed compensation is on record for 3 fiscal years. Olivier Loeillot has spoken on 9 earnings calls and 3 other investor events across 1 company, most recently for Repligen Corp on September 9, 2026. Repligen Corp is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at Repligen Corp includes Dr. Martin D. Madaus (Chairman and Board Member), Martin D. Madaus (Chairman), Tony J. Hunt (Chairman) and 7 others.
“on June 12, 2024, the Board elected Mr. Loeillot as a member of the Board and appointed Karen A. Dawes, the Board's current Chair, to the role of Lead Independent Director, each effective as of the Transition Date.”
Repligen Corp Form 8-K, filed June 14, 2024
· Read the filing
“Repligen Corporation ("Repligen") has appointed Olivier Loeillot, Repligen's President and Chief Commercial Officer, to the role of President and Chief Executive Officer, as successor to Tony J. Hunt, who will serve as Executive Chair of the Repligen board of directors (the "Board"), with such transition to be effective September 1, 2024 (the "Transition Date").”
Repligen Corp Form 8-K, filed June 14, 2024
· Read the filing
Olivier Loeillot on recent calls
“I mean, obviously very happy about how quarter two played out for us. You're right, we grew 13% organic. In fact, the real number was 14 because we lost a portion on tariff refund.”
“Once again, we delivered excellent results in the second quarter our team executed at a high level driving 12 percent reported growth which translated to 13 percent organic growth and 460 basis points of adjusted operating margin expansion reflecting on our strong first half results and with our increased conviction…”
“So I want to start with the first column, which is really we are creating solutions. I mean, you know, when you compete with four big guys who are all like anywhere between four times and ten times bigger than you are, I mean, you have to be differentiated.”
“We are delighted to share our first quarter 2026 results. Great execution once again by our team enabled us to deliver 15% reported revenue growth or 11% organic and 160 basis points of adjusted operating margin expansion.”
